About
About us
Leadership
Investors
Partnership
Science
Overview
CRISPR-cas13
CRISPR-cas12
Scientific Publications & Presentations
Technology Platform
HG-AAV Platform
Animal Model Platform
Manufacturing Capabilities
Pipeline
Pipeline
Disease focus
HG301(RHO-adRP)
HG202(nAMD)
HG204(MDS)
HG004(RPE65-IRDs)
HG302(DMD)
Newsroom
Press release
Nature Biotechnology published the high-fidelity Cas13 protein variant of HuiGene, which accelerated the
HuidaGene Therapeutics Announces IND Active For The Multinational Trial Of HG004 To Treat Inherited Blindness
HuidaGene Announces IND Approval Of The First China Multinational Master Protocol of HG004 By China NMPA
HuidaGene Appoints New Members to the Scientific Advisory Board
HuidaGene Announces Completion of First Patient Enrollment in its Ophthalmic Gene Therapy Candidate HG004 IIT Clinical Trials
Statement: English name changed from "HuiGene Therapeutics Co., Ltd." to "HuidaGene Therapeutics Co., Ltd.e "
Engineered high-fidelity Cas13 variants with minimal collateral RNA targeting
HuidaGene team of scientists collaborate to discover potential new treatment for Duchenne muscular dystrophy
Huidagene Therapeutics Announces 19 Presentations Highlighting Advances in its Gene Therapy Technology Platforms at the 2023 ASGCT Annual Meeting
HuidaGene Therapeutics Announces Publication of the World’s First Guanine Base-Editor
HuidaGene Therapeutics Appoints Alvin Luk as Chief Executive Officer
NSR|HuidaGene's Yang Hui team pioneers disruptive guanine (G) base editor
HuidaGene and Kactus Announce Strategic Collaboration and License Agreement to Promote Commercialization of Next-Generation Gene Editing Enzyme, hfCas12Max®
HuidaGene Therapeutics Receives FDA Rare Pediatric Disease Designation for HG004 to Treat Inherited Blindness
HuidaGene Therapeutics Announces First Patient Dosed Of The World's First Novel CRISPR/Cas13 RNA-Editing Therapy HG202 For Neovascular Age-related Macular Degeneration
HuidaGene Showcases Gene-Editing Based Medicine for Neurological Disease at Japan Society of Gene and Cell Therapy 2023 Annual Meeting
HuidaGene Therapeutics Announces 13 Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
HuidaGene Therapeutics Announces Last Patient Dosed in Clinical Trial of HG004 for the Treatment of Leber Congenital Amaurosis
U.S. FDA Awards Both Rare Pediatric Disease and Orphan Drug Designations to HG204, a CRISPR RNA-editing Therapy, for the Treatment of MECP2 Duplication Syndrome
HuidaGene Therapeutics to Attend BIO-Europe Fall Conference in Munich for Actively Expanding Global Collaboration
HuidaGene Therapeutics Announces First Patient Dosed in Multnational Phase 1/2 Trial of HG004 for Inherited Blindness
Media
Contact us
Get in touch
Careers